
Top news of the week from Specialty Pharmacy Times.

Specialty pharmacy customer service measures are key in achieving optimal patient outcomes.

Adcetris is an antibody-drug conjugate that may improve treatment of cutaneous T cell lymphoma.

Once-daily dose prevented vaginal and oral HIV transmission in animal models.

Biosimilar to rheumatoid arthritis and inflammatory bowel disease drug shows similar efficacy to brand name drug.

Top news of the day from across the health care landscape.

COPD-related costs reduced from therapies that treat moderate-to-severe COPD.

Meaningful clinical activity found from PD-1 blockade treatment in metastatic prostate cancer patients resistant to androgen deprivation.

Perceived memory problems could be linked to stress rather that treatment in breast cancer survivors.

Factors for meeting the varying needs of patients, providers, manufacturers and payors in specialty pharmacy.

Express Scripts has 85 drugs excluded from its formulary list, compared with 154 for CVS.

Debate continues surrounding cost versus cure in hepatitis C treatment.

Viral suppression may translate to safe sex among couple with an HIV positive individual.

People with pale skin, freckles, and red hair carry mutations comparable to an extra 21 years of sun exposure.

Researchers gain insight on genetic variants that influence the development of type 2 diabetes.

Fluorescence lifetime imaging identifies which breast cancer patients will benefit from specific treatments.

A team of 4 transcription factors work together to trigger a cell to turn into a T cell.

Top news of the day from across the health care landscape.

Payers and manufacturers must ensure patients are getting the most value from their therapy.

Funds from social media phenomenon leads to breakthrough discovery in amyotrophic lateral sclerosis (ALS).

Add-on therapy to interferon beta-1a is a potentially groundbreaking oral antibiotic combination.

Neratinib and the combination of veliparib plus carboplatin improves breast cancer outcomes.

Top news from across the health care landscape.

Anti-PD-L1 immunotherapy with an MEK inhibitor may improve treatment of microsatellite-stable metastatic colorectal cancer.

Researchers created an algorithm that can discover how the immune system responds to cancer.

Microscopic silk swimming device may improve treatment for variety of diseases.

Zepatier is already approved in the United States and Canada for treatment of hepatitis C.

Prescribers and patients can no longer blindly rely on simple and straightforward drug delivery in specialty pharmacy.

CDC raises concerns about mother-to-child transmission of hepatitis C virus.

Ipilimumab combined with local peripheral treatments shows promise in malignant melanoma.